All Data
Global Pharmaceutical Dosage Solutions Company
Lead Product(s): AdCOVID
Therapeutic Area: Infections and Infectious Diseases Product Name: AdCOVID
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Altimmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 10, 2020
Details:
Altimmune's agreement with Lonza expands its current clinical and commercial manufacturing strategy for AdCOVID. AdCOVID, a single-dose intranasal vaccine for COVID-19, designed to generate a broad immune response with the unique ability to promote nasal mucosal immunity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MTX-COVAB
Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
In the hamster challenge model, even low MTX-COVAB (5 mg/kg preventive; 10 mg/kg therapeutic) protected against weight loss, a key indicator of disease severity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AM-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AM-301
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Daily treatment with AM-301, beginning right before inoculation, showed effective protection against viral infection. Up to 99.4% reduction of viral titer in human epithelial cell culture was observed after treatment with AM-301 in the study.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Murepavadin
Therapeutic Area: Infections and Infectious Diseases Product Name: POL7080
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: CF Foundation
Deal Size: $3.3 million Upfront Cash: Undisclosed
Deal Type: Funding November 24, 2020
Details:
Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MP0420
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $231.0 million Upfront Cash: $22.0 million
Deal Type: Licensing Agreement October 28, 2020
Details:
Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 .
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Thanatin-derivative antibiotic
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: CARB-X
Deal Size: $18.4 million Upfront Cash: Undisclosed
Deal Type: Funding October 14, 2020
Details:
Award will support the development of the “thanatin derivatives program” belonging to Polyphor’s novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MP0420
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
DARPin® candidates targeting SARS-CoV-2 show robust activity in an aggressive viral challenge hamster model, supporting potential efficacy as therapeutic options in patients with late-stage disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Linoleic Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
The team found out that linoleic acid synergizes with currently utilized COVID-19 therapeutics to suppress replication and shut down the virus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AM-301
Therapeutic Area: Infections and Infectious Diseases Product Name: AM-301
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2020
Details:
AM-301 is a gel which works by forming a protective layer on the nasal mucosa, acting as a physical barrier against airborne pathogens and allergens.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MP0420
Therapeutic Area: Infections and Infectious Diseases Product Name: MP0420
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Swiss Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 11, 2020
Details:
Swiss Government will pay a reservation fee for the right to purchase up to 3.2 million doses of anti-COVID-19 DARPin® candidate, MP0420, for both therapeutic and potential prophylactic use.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
